investingreview.org logo
Vermeiden Sie Betrug, informieren Sie sich und finden Sie das Beste
Nothings Found.

The Top Holdings Changes of Pratt Collard Advisory Partners LLC: Q1 2021 vs. Q2 2021

Ava Hoppe | 6 May, 2023

Pratt Collard Advisory Partners LLC recently filed its quarterly 13F report with the SEC, revealing its top holdings changes for Q1 2021 vs. Q2 2021. The report showed that the firm increased its holdings in some companies, while others saw a reduction. Let's take a closer look at the top holdings changes of Pratt Collard Advisory Partners LLC and what it means for the investors.

First off, the firm increased its stake in Procter & Gamble Co. (PG) by 0.6%. The company now holds 114,977 shares, up from 114,312 in Q1 2021. The value of its holdings in PG increased slightly from $15,481,000 to $15,514,000. This shows that the firm has confidence in the long-term growth prospects of the consumer goods company.

Another company that saw an increase in holdings is Digimarc Corp. (DMRC), with a growth of 18%. Pratt Collard now holds 246,084 shares of DMRC, up from 235,642 shares in Q1 2021. The value of its holdings in DMRC also increased significantly from $6,989,000 to $8,244,000. This move is likely due to the strong earnings growth of the technology company in recent quarters.

On the other hand, Berkshire Hathaway Inc. (BRK-B) saw a meager 0.1% increase in holdings, with Pratt Collard now holding 20,670 shares compared to 20,649 in Q1 2021. The value of its holdings in BRK-B increased slightly from $5,275,000 to $5,745,000. This indicates that although the firm still has confidence in the long-term prospects of the conglomerate, it may have been less bullish on its stock in Q2 2021.

In addition, Pratt Collard decreased its holdings in AbbVie Inc. (ABBV) by a significant 38.5%. The firm went from holding 7,459 shares of ABBV in Q1 2021 to only holding 4,402 shares in Q2 2021. The value of its holdings in ABBV decreased from $807,000 to $496,000. This move could indicate that the firm is losing confidence in the pharmaceutical company's future growth potential.

Overall, Pratt Collard Advisory Partners LLC's 13F report for Q1 2021 vs. Q2 2021 shows a mix of bullish and bearish positions. While the firm increased its holdings in some companies, it reduced its exposure to others. Investors can use this information to gain insight into the firm's strategy and to inform their own investment decisions.

Viele Menschen wurden durch Betrug und Ponzi-Vorhaben verbrannt. Deshalb haben wir diese Website erstellt, um Ihnen als potenziellem Investor dabei zu helfen, die Fakten zu ermitteln, die besten zu finden und Betrugs- und Ponzi-Vorhaben zu vermeiden.

Alle auf dieser Website bereitgestellten Informationen werden ohne Gewähr und nur zu Informationszwecken bereitgestellt.
InvestingReview.org bietet keine Anlageberatung an. InvestingReview.org ist kein Anlageberater und wird von keiner US-amerikanischen oder nicht US-amerikanischen Aufsichtsbehörde unterstützt oder ist mit dieser verbunden.


Kürzlich gesuchte Firmen

Bitte beachten Sie: Die Suchdaten werden von Dritten gesammelt und einmal täglich aktualisiert.

Copyright © 2023 by InvestingReview.org / Alle Rechte vorbehalten.